The global blood plasma market is anticipated to record growth at a CAGR of 6.04% between 2019 and 2027 to generate revenue of $44882 million by 2027. Blood plasma is an integral part of an effective therapeutic treatment plan in various therapies, owing to its potential in battling numerous chronic and life-threatening diseases, namely hemophilia, leukemia, immunodeficiency, and other bleeding diseases. The important driver of the global blood plasma market responsible for market gains is the increase in the patient pool for hemophilia treatment, and the augmented geriatric population. With the increasing aging population worldwide, there is an increased chance of diseases that requires plasma therapy.

GLOBAL BLOOD PLASMA MARKET FORECAST 2020-2028

Global Blood Plasma Market by Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants) by Blood Type (Immunoglobulin, Albumin, Hyperimmunes, Coagulation Factor Concentrates, Other Plasma Fractionation Products) by Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other Application) by Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand Disease (Vwd), Other Application)  by End User (Hospitals and Clinics, Research Laboratories, Academic Institutions) and by Geography.

Request free sample

The global blood plasma market is estimated to record growth at a CAGR of 6.24% during the forecast period, and is anticipated to generate revenue of $48.50 billion by 2028. Blood plasma is a part of active therapeutic treatment in numerous therapies, due to its potential in battling numerous life-threatening and chronic diseases, such as leukemia, hemophilia, immunodeficiency, and other bleeding diseases. The products of blood plasma have proven to be beneficial for patients suffering from such diseases, which have necessitated a more in-depth understanding of their application.

Key factors that are responsible for the global blood plasma market growth are:

  • Increase in the patient pool for hemophilia treatment
  • Rising occurrence of sports injuries
  • Rising prevalence of alpha-1 antitrypsin deficiency (AATD)
  • Rising usage of albumin in therapeutic areas
  • Growing geriatric population

Blood Plasma Market
To know more about this report, request a free sample copy.

The important drivers boosting the growth of the global blood plasma market are the growing usage of albumin in other therapeutic areas, and the growing geriatric population. Albumin was initially used as a volume replacement therapy. However, with the advancement in research and technology, the use of albumin in other therapeutic areas is being exploited. With the growth in the geriatric population, there is a growing demand for blood plasma, since older people are prone to infections due to the weakened immune systems. Immunocompromised people also face immunodeficiency, and the plasma plays a vital role in their treatment.

In 2019, around 38.09% of revenue share was garnered by the neurology category in the therapeutic indication segment. The transplantation category is anticipated to record the fastest growth. Neurology is the branch of medicine that deals with the diagnosis and treatment of diseases associated with the central and peripheral autonomic and somatic nervous systems, including their coverings, blood vessels, and effector tissues. Plasma components may be administered to post-transplant surgery patients, and are also considered major tools for diagnosing various health conditions.

The high costs of blood plasma treatments and the spread of pathogenic contaminants are the major factors hindering the blood plasma market growth. Several emerging blood plasma therapies are widely accepted for therapeutic treatments, but their integration is expensive. Plasma products are prepared from the plasma obtained from donors. This results in the presence of pathogenic contaminants if the plasma collection is not done in accordance with standards.

The report scope of the global blood plasma market includes the segmentation analysis of disorder, therapeutic indication, blood derivatives, and end-user.

Disorder is segmented into:

  • Immunodeficiency Diseases
  • Hypogammaglobulinemia
  • Hemophilia
  • Von Willebrand Disease (vWD)
  • Other Disorders

Therapeutic Indication is segmented into:

  • Neurology
  • Immunology
  • Oncology
  • Transplantation
  • Hematology
  • Rheumatology
  • Pulmonology
  • Other therapeutic indication

Blood Derivatives is segmented into:

  • Immunoglobulin
    • Intravenous immunoglobulin
    • Subcutaneous immunoglobulin
    • Other immunoglobulin types
  • Albumin
  • Hyperimmune
  • Coagulation factor concentrates
  • Other plasma fractionation products

End-user is segmented into:

  • Hospitals and clinics
  • Research laboratories
  • Academic institutions

Geographically, the global blood plasma market has been segmented on the basis of four major regions, which includes:

  • North America: The United States & Canada
  • Asia Pacific: Indonesia, China, India, Thailand, South Korea, Japan, Vietnam, Australia & New Zealand, and Rest of Asia Pacific
  • Europe: Germany, Italy, Russia, The United Kingdom, France, Belgium, Poland, and Rest of Europe
  • Rest of World: Latin America, the Middle East & Africa

In terms of geography, North America dominated the market with a revenue share of approx. 39.97% in 2019. The blood plasma market of North America is expected to hold the largest share by 2028. North America is the center of blood plasma therapy R&D, which is integrated into several treatment methods in the region. The region has generated various advanced modalities pertaining to blood plasma and has also developed such therapies on a large scale.

The Asia Pacific region is estimated to record the highest CAGR. China has dominated the Asia Pacific market as a result of the rising number of organizations that ensure blood plasma supply. Japan stood at second with substantial contributions to the blood plasma market as there is limited accessibility of domestic plasma, which has hampered the overall yield.

The major market players of the global blood plasma market are:

  • Arthrex
  • Baxter International
  • Biotest AG
  • Fusion Health Care
  • Takeda Pharmaceutical Company
  • Others

Key strategies adopted by some of the blood plasma companies:

In January 2020, Adma Biologics entered into a supply and manufacturing agreement to sell and produce plasma-derived transitional fractions. In March 2019, Biotest acknowledged approval in thirteen countries in Europe for the abridged solvent volume by half for the factor VIII concentrate Haemoctin(R) SDH.

Key findings of the global blood plasma market:

  • Immunoglobulin blood derivatives hold the largest market share.
  • There is an increase in the use of synthetic/recombinant products.
  • There has been an increase in the incidence of hemophilia.
  • There is an increased awareness among the general population.
  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    •    KEY DRIVERS
      • WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
      • GROWING USAGE OF ALBUMIN IN OTHER THERAPEUTIC AREAS
      • GROWING GERIATRIC POPULATION
      • RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
      • INCREASE IN THE PATIENT POOL FOR HEMOPHILIA TREATMENT
      • RISE IN OCCURRENCE OF SPORTS INJURIES
    •    KEY RESTRAINTS
      • INCREASING USAGE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
      • HIGH COSTS OF BLOOD PLASMA TREATMENTS
      • ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
      • SPREAD OF PATHOGENIC CONTAMINANTS
      • HIGH REGULATIONS IN THE MARKET
  1. KEY ANALYTICS
    •    PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • PLASMA THERAPEUTICS REGULATION
    • CLINICAL GUIDELINES
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY MODE OF DELIVERY
    • INFUSION SOLUTIONS
    • GELS
    • SPRAYS
    • BIOMEDICAL SEALANTS
  3. MARKET BY DISORDER
    • IMMUNODEFICIENCY DISEASE
    • HYPOGAMMAGLOBULINEMIA
    • HEMOPHILIA
    • VON WILLEBRAND DISEASE (VWD)
    • OTHER DISORDERS
  4. MARKET BY BLOOD PLASMA DERIVATIVES
    •    IMMUNOGLOBULIN
      • INTRAVENOUS IMMUNOGLOBULIN
      • SUBCUTANEOUS IMMUNOGLOBULIN
      • OTHER IMMUNOGLOBULIN TYPES
    • ALBUMIN
    • HYPERIMMUNE
    • COAGULATION FACTOR CONCENTRATES
    • OTHER PLASMA FRACTIONATION PRODUCTS
  5. MARKET BY THERAPEUTIC INDICATION
    • NEUROLOGY
    • IMMUNOLOGY
    • ONCOLOGY
    • TRANSPLANTATION
    • HEMATOLOGY
    • RHEUMATOLOGY
    • PULMONOLOGY
    • OTHER THERAPEUTIC INDICATION
  6. MARKET BY END-USER
    • HOSPITALS AND CLINICS
    • RESEARCH LABORATORIES
    • ACADEMIC INSTITUTIONS
  7. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    •    EUROPE
      • THE UNITED KINGDOM
      • GERMANY
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • JAPAN
      • CHINA
      • AUSTRALIA & NEW ZEALAND
      • INDIA
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • ADMA BIOLOGICS
    • ARTHREX
    • BIO PRODUCTS LABORATORY
    • BAXTER INTERNATIONAL
    • BIOTEST AG
    • CERUS CORPORATION (CERUS)
    • CHINA BIOLOGIC PRODUCTS
    • CSL LIMITED
    • FUSION HEALTH CARE
    • GREEN CROSS HOLDINGS CORPORATION
    • GRIFOLS
    • LFB
    • OCTAPHARMA
    • TAKEDA PHARMACEUTICAL COMPANY
    • KEDRION BIOPHARMA INC

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – BLOOD PLASMA

TABLE 2: GLOBAL BLOOD PLASMA MARKET, BY DISORDER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 3: GLOBAL BLOOD PLASMA MARKET, BY DISORDER, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 4: GLOBAL IMMUNODEFICIENCY DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: GLOBAL IMMUNODEFICIENCY DISEASES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 6: GLOBAL HYPOGAMMAGLOBULINEMIA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: GLOBAL HYPOGAMMAGLOBULINEMIA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 8: GLOBAL HEMOPHILIA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 9: GLOBAL HEMOPHILIA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 10: GLOBAL VON WILLEBRAND DISEASE (VWD) MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: GLOBAL VON WILLEBRAND DISEASE (VWD) MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 12: GLOBAL OTHER DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 13: GLOBAL OTHER DISORDERS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 14: GLOBAL BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 15: GLOBAL BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 20: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 21: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 22: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 23: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 24: GLOBAL OTHER IMMUNOGLOBULIN TYPE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 25: GLOBAL OTHER IMMUNOGLOBULIN TYPE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 26: GLOBAL ALBUMIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 27: GLOBAL ALBUMIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 28: GLOBAL HYPERIMMUNE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 29: GLOBAL HYPERIMMUNE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 30: GLOBAL COAGULATION FACTOR CONCENTRATES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 31: GLOBAL COAGULATION FACTOR CONCENTRATES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 32: GLOBAL OTHER PLASMA FRACTIONATION PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 33: GLOBAL OTHER PLASMA FRACTIONATION PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 34: GLOBAL BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 35: GLOBAL BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 36: GLOBAL NEUROLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 37: GLOBAL NEUROLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 38: GLOBAL IMMUNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 39: GLOBAL IMMUNOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 40: GLOBAL ONCOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 41: GLOBAL ONCOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 42: GLOBAL TRANSPLANTATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 43: GLOBAL TRANSPLANTATION MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 44: GLOBAL HEMATOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 45: GLOBAL HEMATOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 46: GLOBAL RHEUMATOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 47: GLOBAL RHEUMATOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 48: GLOBAL PULMONOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 49: GLOBAL PULMONOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 50: GLOBAL OTHER THERAPEUTIC INDICATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 51: GLOBAL OTHER THERAPEUTIC INDICATION MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 52: GLOBAL BLOOD PLASMA MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 53: GLOBAL BLOOD PLASMA MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 54: GLOBAL HOSPITALS AND CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 55: GLOBAL HOSPITALS AND CLINICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 56: GLOBAL RESEARCH LABORATORIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 57: GLOBAL RESEARCH LABORATORIES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 58: GLOBAL ACADEMIC INSTITUTIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 59: GLOBAL ACADEMIC INSTITUTIONS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 60: GLOBAL BLOOD PLASMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 61: GLOBAL BLOOD PLASMA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 62: NORTH AMERICA BLOOD PLASMA MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 63: NORTH AMERICA BLOOD PLASMA MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 64: EUROPE BLOOD PLASMA MARKET, BY COUNTRY, HISTORICAL YEARS 2016-2019 (IN $ MILLION)

TABLE 65: EUROPE BLOOD PLASMA MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 66: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 67: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 68: REST OF BLOOD PLASMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 69: REST OF BLOOD PLASMA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: IMMUNOGLOBULIN INFUSIONS SIDE EFFECTS

FIGURE 6: ROLE OF FIBRIN SEALANT IN COAGULATION CASCADE

FIGURE 7: GLOBAL BLOOD PLASMA MARKET, BY DISORDER, IN 2019

FIGURE 8: GLOBAL BLOOD PLASMA MARKET, BY IMMUNODEFICIENCY DISEASE, 2020-2028 (IN $ MILLION)

FIGURE 9: GLOBAL BLOOD PLASMA MARKET, BY HYPOGAMMAGLOBULINEMIA, 2020-2028 (IN $ MILLION)

FIGURE 10: GLOBAL BLOOD PLASMA MARKET, BY HEMOPHILIA, 2020-2028 (IN $ MILLION)

FIGURE 11: GLOBAL BLOOD PLASMA MARKET, BY VON WILLEBRAND DISEASE (VWD), 2020-2028 (IN $ MILLION)

FIGURE 12: GLOBAL BLOOD PLASMA MARKET, BY OTHER DISORDERS, 2020-2028 (IN $ MILLION)

FIGURE 13: GLOBAL BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, IN 2019

FIGURE 14: GLOBAL BLOOD PLASMA MARKET, BY IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)

FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)

FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)

FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER IMMUNOGLOBULIN TYPES, 2020-2028 (IN $ MILLION)

FIGURE 18: GLOBAL BLOOD PLASMA MARKET, BY ALBUMIN, 2020-2028 (IN $ MILLION)

FIGURE 19: GLOBAL BLOOD PLASMA MARKET, BY HYPERIMMUNE, 2020-2028 (IN $ MILLION)

FIGURE 20: HYPERIMMUNES ISOLATION PROCESS

FIGURE 21: GLOBAL BLOOD PLASMA MARKET, BY COAGULATION FACTOR CONCENTRATES, 2020-2028 (IN $ MILLION)

FIGURE 22: GLOBAL BLOOD PLASMA MARKET, BY OTHER PLASMA FRACTIONATION PRODUCTS, 2020-2028 (IN $ MILLION)

FIGURE 23: GLOBAL BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, IN 2019

FIGURE 24: GLOBAL BLOOD PLASMA MARKET, BY NEUROLOGY, 2020-2028 (IN $ MILLION)

FIGURE 25: GLOBAL BLOOD PLASMA MARKET, BY IMMUNOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 26: GLOBAL BLOOD PLASMA MARKET, BY ONCOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 27: GLOBAL BLOOD PLASMA MARKET, BY TRANSPLANTATION, 2020-2028 (IN $ MILLION)

FIGURE 28: GLOBAL BLOOD PLASMA MARKET, BY HEMATOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 29: GLOBAL BLOOD PLASMA MARKET, BY RHEUMATOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 30: LUPUS INFECTION SYMPTOMS

FIGURE 31: GLOBAL BLOOD PLASMA MARKET, BY PULMONOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 32: GLOBAL BLOOD PLASMA MARKET, BY OTHER THERAPEUTIC INDICATION, 2020-2028 (IN $ MILLION)

FIGURE 33: GLOBAL BLOOD PLASMA MARKET, BY END-USER, IN 2019

FIGURE 34: GLOBAL BLOOD PLASMA MARKET, BY HOSPITALS AND CLINICS, 2020-2028 (IN $ MILLION)

FIGURE 35: GLOBAL BLOOD PLASMA MARKET, BY RESEARCH LABORATORIES, 2020-2028 (IN $ MILLION)

FIGURE 36: GLOBAL BLOOD PLASMA MARKET, BY ACADEMIC INSTITUTIONS, 2020-2028 (IN $ MILLION)

FIGURE 37: NORTH AMERICA BLOOD PLASMA MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 38: THE UNITED STATES BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 39: CANADA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 40: EUROPE BLOOD PLASMA MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 41: THE UNITED KINGDOM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 42: GERMANY BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 43: FRANCE BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 44: ITALY BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 45: RUSSIA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 46: BELGIUM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 47: POLAND BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 48: REST OF EUROPE BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 49: ASIA PACIFIC BLOOD PLASMA MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 50: JAPAN BLOOD PLASMA, 2020-2028 (IN $ MILLION)

FIGURE 51: CHINA BLOOD PLASMA, 2020-2028 (IN $ MILLION)

FIGURE 52: AUSTRALIA & NEW ZEALAND BLOOD PLASMA, 2020-2028 (IN $ MILLION)

FIGURE 53: INDIA BLOOD PLASMA, 2020-2028 (IN $ MILLION)

FIGURE 54: SOUTH KOREA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 55: THAILAND BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 56: INDONESIA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 57: VIETNAM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 58: REST OF ASIA PACIFIC BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 59: REST OF WORLD BLOOD PLASMA MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 60: LATIN AMERICA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 61: MIDDLE EAST & AFRICA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

  1. MARKET BY MODE OF DELIVERY
    • INFUSION SOLUTIONS
    • GELS
    • SPRAYS
    • BIOMEDICAL SEALANTS
  2. MARKET BY BLOOD TYPE
    •    IMMUNOGLOBULIN
      • INTRAVENOUS IMMUNOGLOBULIN
      • SUBCUTANEOUS IMMUNOGLOBULIN
      • OTHER IMMUNOGLOBULIN TYPE
    • ALBUMIN
    • HYPERIMMUNES
    • COAGULATION FACTOR CONCENTRATES
    • OTHER PLASMA FRACTIONATION PRODUCTS
  3. MARKET BY THERAPEUTIC INDICATION
    • IMMUNOLOGY
    • ONCOLOGY
    • PULMONOLOGY
    • RHEUMATOLOGY
    • TRANSPLANTATION
    • NEUROLOGY
    • HEMATOLOGY
    • OTHER APPLICATION
  4. MARKET BY APPLICATION
    • HEMOPHILIA
    • HYPOGAMMAGLOBULINEMIA
    • IMMUNODEFICIENCY DISEASES
    • VON WILLEBRAND DISEASE (VWD)
    • OTHER APPLICATION
  5. MARKET BY END USER
    • HOSPITALS AND CLINICS
    • RESEARCH LABORATORIES
    • ACADEMIC INSTITUTIONS
  6. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    •    EUROPE
      • FRANCE
      • GERMANY
      • THE UNITED KINGDOM
      • ITALY
      • SPAIN
      • REST OF EUROPE
    •    ASIA PACIFIC
      • JAPAN
      • CHINA
      • AUSTRALIA
      • INDIA
      • SOUTH KOREA
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Choose License Type